[ Vivace Therapeutics raises $25M in Series B funding ]
Vivace Therapeutics has raised $25 million in Series B funding.
Founded in 2014, Vivace Therapeutics is an oncology-based pharmaceutical company that discovers, develops and provides therapeutics for cancer. The company says its drug discovery and development efforts will initially focus on inhibitors of the Hippo-YAP signaling pathway.
Vivace is also developing novel therapeutic antibodies — called BINspecific™ antibodies (bi-specific irreversible cell-type specific antibodies)— that bind in a nearly irreversible and cell-type specific manner to target cells.
|City||San Mateo, California|
|Founder / CEO||Sofie Qiao|
|Investors||WuXi Healthcare Ventures|
|Mission Bay Capital|
|Previous Investors||Canaan Partners|
|WuXi Healthcare Ventures|